Minimal residual disease in multiple myeloma: the movement towards response-adapted therapy

Minimal residual disease (MRD) testing serves as a powerful prognostic tool and surrogate trial endpoint in multiple myeloma. Evaluated through bone marrow, imaging, or peripheral blood techniques, achieving MRD negativity strongly correlates with improved survival outcomes. Consequently, clinical MRD status drives response-adapted therapy, guiding personalized treatment escalation, de-escalation, or discontinuation.